

February 14, 2022

Company name: Amvis Holdings, Inc.
Name of representative: Keiichi Shibahara, Representative Director and CEO
Securities code: 7071; Tokyo Stock Exchange JASDAQ (Standard)
Inquiries: Tetsuya Nakagawa, Director and CFO

Notice of the Impact of NHI Medical Fee Revisions on Our Financial Performance

A report by the Central Social Insurance Medical Council on February 9, 2022 announced details of NHI medical fee revisions for FY2022. Amvis Holdings, Inc. (Chuo-ku, Tokyo; Representative Director and CEO: Keiichi Shibahara) outlines the impact of these revisions on its consolidated financial performance below.

NHI Medical Fee Revisions in Relation to Our Business

The main priority of the FY2022 NHI medical fee revisions is to build an efficient, effective, and high-quality medical care system that can respond to COVID-19 and other infections, in light of recent medical problems, while maintaining the trend of previous revisions. One specific direction is to “ensure high-quality home medical care and home nursing care.”

As demand for home medical care is expected to increase significantly in the medium to long term, it will be important for medical institutions responsible for home medical care, municipalities, and medical associations to cooperate and provide medical and nursing care seamlessly to build an efficient, effective, and high-quality home care and home nursing system.

Based on these directions for home nursing care, extensive discharge support and guidance were evaluated so that patients with high medical dependency can smoothly transition from hospital to home, and a new evaluation was established for advanced care and management by highly specialized nurses. In addition, some requirements have been revised to encourage a flexible response on site in accordance with needs.

Impact on Financial Performance

At this time, the impact of NHI medical fee revisions on our consolidated financial performance is expected to be immaterial, and if any matters that should be disclosed arise in the future, they will be announced promptly.

Overview of Ishinkan, Operated by the Amvis Group

Ishinkan is a healthcare facility in which nurses and other caregivers provide round-the-clock care. Ishinkan actively accepts patients who are in the terminal stage of cancer, who are on respirators, who have had tracheostomies, who have specific diseases requiring them to be repeatedly in and out of hospital, or who require end-of-life nursing and caregiving. Ishinkan actively cooperates with regional medical institutions, pharmacies, and nursing care facilities, and functions as “shared hospital beds.”

Note:

As of the end of February 2022, we expect to operate 50 facilities (2,390 beds).

Company Profile

Name: Amvis Holdings, Inc.
Location: 4F Yaesu Mitsui Building, 2-7-2 Yaesu, Chuo-ku, Tokyo, Japan
Representative: Keiichi Shibahara
Established: October 2016
Business: Operation of Ishinkan, healthcare facilities specializing in nursing and nursing care in the chronic and terminal stages of illness, for patients with high medical dependency